Does perhexiline improve cardiac energetic impairment, diastolic dysfunction, and exercise capacity in patients with symptomatic hypertrophic cardiomyopathy?
Perhexiline improves cardiac energetics, diastolic function, and exercise capacity in symptomatic hypertrophic cardiomyopathy, providing a rationale for metabolic therapies in this condition.
In symptomatic hypertrophic cardiomyopathy, perhexiline, a modulator of substrate metabolism, ameliorates cardiac energetic impairment, corrects diastolic dysfunction, and increases exercise capacity. This study supports the hypothesis that energy deficiency contributes to the pathophysiology and provides a rationale for further consideration of metabolic therapies in hypertrophic cardiomyopathy.
Abozguia et al. (Tue,) studied this question.